Browsing by Subject "Ki67"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Publication
    Open Access
    Clinical significance of ALDH1A1 and Ki67 expression in women with breast carcinoma
    (Universidad de Murcia, Departamento de Histología e Histopatología, 2025) Zong Yuxuan; Ma Shuang; Yin Jiaxin; Qiao Na; Zhang Dongmei; Niu Zhaoyang; Zhao Ye; Zhou Fei; Biología Celular e Histología
    Background. Breast cancer is the most prominent cancer among women worldwide, with a two-fold incidence in China compared to the worldwide incidence. ALDH1A1, catalyzing the oxidation of intracellular aldehydes and converting retinol into retinoic acid, serves as a biomarker of early stem cell differentiation. Ki67 levels are prognostic or residual risk biomarkers after primary therapy and can predict the effects of systemic therapies or monitor patients for sustained response or resistance to the administered therapies. This study aimed to investigate the correlation between ALDH1A1 and Ki67 expression and clinicopathological parameters among women with breast cancer. Methods. Breast cancer tissue specimens were obtained from the Department of Pathology at the First Hospital of Qiqihar. Indirect fluorescent immunostaining was used to assess the expression of ALDH1A1 and Ki67 in breast cancer and healthy tissues. Associations between ALDH1A1 and Ki67 expression and clinicopathological parameters of breast cancer were evaluated using the chi-square test. A p-value less than 0.05 was considered statistically significant. The correlation between ALDH1A1 and Ki67 expression was assessed using Spearman’s rank correlation analysis. Results. ALDH1A1 and Ki67 were upregulated in breast cancer tissue compared with normal breast tissue (p<0.05). Furthermore, ALDH1A1 expression was further upregulated with an advancement in breast cancer grade, i.e., ALDH1A1 expression levels were higher in patients with stage III/IV breast cancer than in those with stage I/II breast cancer. Furthermore, ALDH1A1 and Ki67 were upregulated in the presence of lymphatic metastasis. Conclusion. ALDH1A1 may be considered a pathognomonic marker for breast cancer. ALDH1A1 and Ki67 expression are significantly positively correlated in women with breast cancer.
  • Thumbnail Image
    Publication
    Open Access
    Correlation of securin and Ki67 in invasive breast carcinoma
    (Universidad de Murcia. Departamento de Biología Celular e Histología, 2019) Mamdouh Talaat, Iman; Akram Hamoudi, Rifat; Mahmoud Yakout, Nada; Youssef Oweiss, Nagwa; Mohammed Omar, Abbas
    Aims. To identify the role of securin (PTTG) as a prognostic marker in invasive breast carcinoma and its possible relation to ki67 and to evaluate the use of ImmunoRatio® as a tool for calculating ki67 and securin labelling indices. Methods. Securin and ki67 immunohistochemical staining were performed on tissue microarray sections representative of 118 patients diagnosed with invasive breast carcinoma from 2005 to 2011. Assessment of immunohistochemical staining was carried out using both visual counting and ImmunoRatio®. The 118 cases were categorized into 2 groups according to their clinical outcome; the first group (G1) (n=77) comprised patients who were diseasefree while the second group (G2) (n=41) included patients who developed either recurrence and/or metastasis at the end of 24 months follow-up duration. Results. Both securin and ki67 labelling indices (LIs) obtained by visual counting were significantly higher in G2, while only securin LIs acquired by ImmunoRatio® were significantly higher in G2. Securin assessment by visual counting was the most accurate (AUC=0.775) in identifying patients who will likely suffer from recurrence and/or distant metastasis. Pearson correlation showed r=0.638, p<0.001 for Ki67 and r=0.671, p<0.001 for securin. Linear regression analysis showed a significant correlation between ki67 and securin, B=1.75, p<0.001. Conclusion. The present results suggest that securin may add to the prognostic value of ki67 in highlighting intra-tumoural heterogeneity in invasive breast carcinoma patients with poor clinical outcome. In addition, the study showed that since securin has a visual counting cutoff with more than 1%, making it easier to use as a breast cancer biomarker in conjunction with ki67 to predict the outcome of the cases more accurately than using only ki67. However, a multivariate analysis on a larger cohort of patients is mandatory to test its potential prognostic value.
  • Thumbnail Image
    Publication
    Open Access
    Phosphorylated protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) expression in breast cancer is correlated with malignant proliferation and histological grading
    (Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2025) Yang, Xiaosi; Duan, Shuqiang; Zha, Jie; Jiang, Tao; Ye, Chun; Yu, Shuihong; Biología Celular e Histología
    This study aims to detect the expression of phosphorylated PERK in breast cancer using immunohistochemistry and explore its significance. We examined 134 cases of formalin-fixed and paraffin-embedded breast cancer tissues. It was found that the expression of phosphorylated PERK in ductal carcinoma was higher than that in lobular carcinoma, and the difference between them was statistically significant, suggesting that phosphorylated PERK played different roles in the occurrence and development of different types of breast cancer. Compared with Ki-67-negative breast cancer tissues, phosphorylated PERK has higher expression in Ki-67-positive tissues and is positively correlated with Ki67 expression, indicating that phosphorylated PERK plays an important role in breast cancer's malignant proliferation and progression. We also found a positive correlation between phosphorylated PERK expression and the histological grading of invasive ductal carcinoma, indicating that phospho-rylated PERK plays an important role in the differentiation of invasive ductal carcinoma. Our study revealed the differential expression of phosphorylated PERK in subtypes of breast cancer. It contributed to the malignant proliferation of breast cancer and tissue differentiation of invasive ductal carcinoma of the breast.